Meds, Mind, Body & Benefits > Research News & Studies

Enochian BioSciences

<< < (2/2)

MitchMiller:
Thought it was interesting that Gilead has partnered with a company that is also reengineering NK cells.  However, Gilead states they will be targeting cancer.  Let's hope they don't try to build a patent wall to block competitors like Enochian.

https://pharmaphorum.com/news/gilead-combs-shoreline-for-nk-cell-therapies-in-2-3bn-alliance/

MitchMiller:
In the latest slide deck from Enochian BioScience's recent corporate presentation, they state that the test subject is still undetectable after 360 days, after stopping ART.

The company is hoping to establish a path toward human trials with the FDA by the end of the year.

Go to slide 43 in the presentation:

http://www.enochianbio.com/wp-content/uploads/2021/09/HCW-Investor-Deck_09.13.2021pdf.pdf

Navigation

[0] Message Index

[*] Previous page

Go to full version